6β-PGI1 is a stable PGI2 analog resistant to hydrolysis in aqueous solutions. 6β-PGI1 has a much longer half-life than PGI2, but a greatly reduced molar potency for receptor mediated function. 6β-PGI1 has a Kact for adenylate cyclase in NCB-20 cells of 4.2 μM compared with 18 nM for PGI2. The potency for vasodilation and inhibition of platelet aggregation is about 1% of PGI2.
HMS-I1 Hydrobromide is a probe that works by destroying heterochromatin mediated transcriptional gene silencing and is used for studies of heterochromatin formation and function.
6α-Prostaglandin I1 (6α-PGI1) is a stable Prostaglandin I2 (PGI2) analog resistant to hydrolysis in aqueous solutions. 6α-PGI1 promotes cyclic AMP accumulation in human thyroid slices and cells in a concentration dependent manner. However, it is about 10-fold less potent than the β-isomer and 100-fold less potent than PGI2 in eliciting the response. 6α-PGI1 exhibits an IC50 of 350 ng ml for inhibition of ADP-induced platelet aggregation, which is nearly 900-fold higher than that observed for PGI2 (0.4 ng ml).
Angiotensin I II (1-6) TFA is a chemical compound comprising amino acids 1-6. It is derived from the Angiotensin I II peptide, which is formed by the cleavage of the precursor angiotensinogen by renin. The resulting Angiotensin I is then hydrolyzed by angiotensin-converting enzyme (ACE) to produce biologically active Angiotensin II. Angiotensin II has been extensively studied for its potential applications in the treatment of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy[1][2][3].